BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McNeil MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, Jackson LA, Omer SB, Jacobsen SJ, DeStefano F. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine 2014;32:5390-8. [PMID: 25108215 DOI: 10.1016/j.vaccine.2014.07.073] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Stafford IA, Parchem JG, Sibai BM. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. Am J Obstet Gynecol 2021;224:484-95. [PMID: 33529575 DOI: 10.1016/j.ajog.2021.01.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
2 Esposito D, Titievsky L, Beachler DC, Hawes JCL, Isturiz R, Scott DA, Gangemi K, Maroko R, Hall-Murray CK, Lanes S. Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population. Vaccine 2018;36:8084-93. [PMID: 30448335 DOI: 10.1016/j.vaccine.2018.10.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Newcomer SR, Xu S, Kulldorff M, Daley MF, Fireman B, Glanz JM. A primer on quantitative bias analysis with positive predictive values in research using electronic health data. J Am Med Inform Assoc 2019;26:1664-74. [PMID: 31365086 DOI: 10.1093/jamia/ocz094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kuntz J, Crane B, Weinmann S, Naleway AL; Vaccine Safety Datalink Investigator Team. Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine 2018;36:1524-7. [PMID: 29456017 DOI: 10.1016/j.vaccine.2018.02.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
5 Malenfant JM, Hochstadt J, Nolan B, Barrett K, Corriveau D, Dee D, Harris M, Herzig-Marx C, Nair VP, Wyner Z, Brown JS. Cross-Network Directory Service: Infrastructure to enable collaborations across distributed research networks. Learn Health Syst 2019;3:e10187. [PMID: 31245605 DOI: 10.1002/lrh2.10187] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Groom HC, Crane B, Naleway AL, Weintraub E, Daley MF, Wain K, Beth Kurilo M, Burganowski R, DeSilva MB, Donahue JG, Glenn SC, Goddard K, Jackson ML, Kharbanda EO, Lewis N, Lou Y, Lugg M, Scotty E, Sy LS, Williams JTB, Irving SA. Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems. Vaccine 2021:S0264-410X(21)01656-X. [PMID: 34980508 DOI: 10.1016/j.vaccine.2021.12.048] [Reference Citation Analysis]
7 Kamidani S, Rostad CA, Anderson EJ. COVID-19 vaccine development: a pediatric perspective. Curr Opin Pediatr 2021;33:144-51. [PMID: 33278108 DOI: 10.1097/MOP.0000000000000978] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
8 Klein NP, Lewis E, McDonald J, Fireman B, Naleway A, Glanz J, Jackson LA, Donahue JG, Jacobsen SJ, Weintraub E, Baxter R. Risk factors and familial clustering for fever 7-10days after the first dose of measles vaccines. Vaccine 2017;35:1615-21. [PMID: 28233624 DOI: 10.1016/j.vaccine.2017.02.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
9 Deady M, Ezzeldin H, Cook K, Billings D, Pizarro J, Plotogea AA, Saunders-Hastings P, Belov A, Whitaker BI, Anderson SA. The Food and Drug Administration Biologics Effectiveness and Safety Initiative Facilitates Detection of Vaccine Administrations From Unstructured Data in Medical Records Through Natural Language Processing. Front Digit Health 2021;3:777905. [PMID: 35005697 DOI: 10.3389/fdgth.2021.777905] [Reference Citation Analysis]
10 Haber P, Arana J, Pilishvili T, Lewis P, Moro PL, Cano M. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015. Vaccine 2016;34:6330-4. [PMID: 27836437 DOI: 10.1016/j.vaccine.2016.10.052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
11 De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to differential and non-differential disease- and exposure misclassification in studies of vaccine effectiveness. PLoS One 2018;13:e0199180. [PMID: 29906276 DOI: 10.1371/journal.pone.0199180] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
12 Sarti L, Lezmi G, Mori F, Giovannini M, Caubet JC. Diagnosis and management of hypersensitivity reactions to vaccines. Expert Rev Clin Immunol 2020;16:883-96. [PMID: 32838592 DOI: 10.1080/1744666X.2020.1814745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Moro PL, Woo EJ, Marquez P, Cano M. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019. Vaccine 2020;38:5923-6. [PMID: 32709434 DOI: 10.1016/j.vaccine.2020.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hedrick SM. The Imperative to Vaccinate. J Pediatr 2018;201:259-63. [PMID: 30054163 DOI: 10.1016/j.jpeds.2018.06.041] [Reference Citation Analysis]
15 Bravo-Alcántara P, Pérez-Vilar S, Molina-León HF, Sturkenboom M, Black S, Zuber PLF, Maure C, Castro JL; L.A.N.V.A.P. (Latin American Network for VAccine Pharmacovigilance). Building capacity for active surveillance of vaccine adverse events in the Americas: A hospital-based multi-country network. Vaccine 2018;36:363-70. [PMID: 28803714 DOI: 10.1016/j.vaccine.2017.04.069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
16 Hoppe C, Obermeier P, Muehlhans S, Alchikh M, Seeber L, Tief F, Karsch K, Chen X, Boettcher S, Diedrich S, Conrad T, Kisler B, Rath B. Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study. Drug Saf 2016;39:977-88. [PMID: 27350063 DOI: 10.1007/s40264-016-0437-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
17 Kesselheim AS, Darrow JJ, Kulldorff M, Brown BL, Mitra-majumdar M, Lee CC, Moneer O, Avorn J. An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19: Analysis reviews the Food and Drug Administration's critical vaccine approval role with implications for COVID-19 vaccines. Health Affairs 2021;40:25-32. [DOI: 10.1377/hlthaff.2020.01620] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
18 Velsko S, Bates T. A Conceptual Architecture for National Biosurveillance: Moving Beyond Situational Awareness to Enable Digital Detection of Emerging Threats. Health Secur 2016;14:189-201. [PMID: 27314659 DOI: 10.1089/hs.2015.0063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
19 Dodd C, Andrews N, Petousis-Harris H, Sturkenboom M, Omer SB, Black S. Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions. BMJ Glob Health 2021;6:e003540. [PMID: 34011501 DOI: 10.1136/bmjgh-2020-003540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Moraes-Fontes MF, Antunes AM, Gruner H, Riso N. Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal. Int J Rheumatol 2016;2016:2845617. [PMID: 27069477 DOI: 10.1155/2016/2845617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, Li R, Klein NP, Hambidge SJ, Naleway AL, Lugg MM, Jackson ML, King JP, DeStefano F, Omer SB, Orenstein WA. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol 2015;126:1069-74. [PMID: 26444109 DOI: 10.1097/AOG.0000000000001066] [Cited by in Crossref: 73] [Cited by in F6Publishing: 42] [Article Influence: 12.2] [Reference Citation Analysis]
22 Miller ER, McNeil MM, Moro PL, Duffy J, Su JR. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome. Vaccine 2020;38:7458-63. [PMID: 33039207 DOI: 10.1016/j.vaccine.2020.09.072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing Vaccine Safety Capacity Globally: A Lifecycle Perspective. Am J Prev Med 2015;49:S364-76. [PMID: 26590436 DOI: 10.1016/j.amepre.2015.09.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Destefano F, Offit PA, Fisher A. Vaccine Safety. Plotkin's Vaccines. Elsevier; 2018. pp. 1584-1600.e10. [DOI: 10.1016/b978-0-323-35761-6.00082-1] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015. Vaccine 2016;34:2507-12. [PMID: 27015735 DOI: 10.1016/j.vaccine.2016.03.048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
26 Moro PL, McNeil MM. Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines. Expert Rev Vaccines 2021. [PMID: 34957900 DOI: 10.1080/14760584.2022.2019020] [Reference Citation Analysis]
27 Xu S, Hong V, Sy LS, Glenn SC, Ryan DS, Morrissette K, Nelson JC, Hambidge SJ, Crane B, Zerbo O, Desilva MB, Glanz JM, Donahue JG, Liles E, Duffy J, Qian L. Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.04.037] [Reference Citation Analysis]
28 Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69:1-41. [PMID: 33417592 DOI: 10.15585/mmwr.rr6909a1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
29 Daley MF, Shoup JA, Newcomer SR, Jackson ML, Groom HC, Jacobsen SJ, McLean HQ, Klein NP, Weintraub ES, McNeil MM, Glanz JM. Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule. Acad Pediatr 2018;18:754-62. [PMID: 29604461 DOI: 10.1016/j.acap.2018.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Weinmann S, Irving SA, Koppolu P, Naleway AL, Belongia EA, Hambidge SJ, Jackson ML, Klein NP, Lewin B, Liles E, Marin M, Smith N, Weintraub E, Chun C. Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine 2020;38:5880-4. [PMID: 32444193 DOI: 10.1016/j.vaccine.2020.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing vaccine safety capacity globally: A lifecycle perspective. Vaccine 2015;33 Suppl 4:D46-54. [PMID: 26433922 DOI: 10.1016/j.vaccine.2015.06.073] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
32 Sukumaran L, McCarthy NL, Li R, Weintraub ES, Jacobsen SJ, Hambidge SJ, Jackson LA, Naleway AL, Chan B, Tao B, Gee J. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. Vaccine 2015;33:4446-50. [PMID: 26209836 DOI: 10.1016/j.vaccine.2015.07.037] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
33 McCarthy NL, Gee J, Sukumaran L, Weintraub E, Duffy J, Kharbanda EO, Baxter R, Irving S, King J, Daley MF, Hechter R, McNeil MM. Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults. Pediatrics 2016;137:e20152970. [PMID: 26908690 DOI: 10.1542/peds.2015-2970] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
34 Qiu Z, Zhu Y. A Novel Structure of Blockchain Applied in Vaccine Quality Control: Double-Chain Structured Blockchain System for Vaccine Anticounterfeiting and Traceability. J Healthc Eng 2021;2021:6660102. [PMID: 33828824 DOI: 10.1155/2021/6660102] [Reference Citation Analysis]
35 Mcmahon AW, Wharton GT, Bonnel R, Decelle M, Swank K, Testoni D, Cope JU, Smith PB, Wu E, Murphy MD. Pediatric post-marketing safety systems in North America: assessment of the current status: Pediatric Post-Marketing Safety Systems. Pharmacoepidemiol Drug Saf 2015;24:785-92. [DOI: 10.1002/pds.3813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
36 Maro JC, Eworuke E, Hou L, Welch EC, Goulding MR, Izem R, Lee JY, Toh S, Fireman B, Nguyen MD. Conducting prospective sequential surveillance in real-world dynamic distributed databases. Pharmacoepidemiol Drug Saf 2020;29:1331-5. [PMID: 32449261 DOI: 10.1002/pds.5002] [Reference Citation Analysis]
37 Haber P, Moro PL, Ng C, Lewis PW, Hibbs B, Schillie SF, Nelson NP, Li R, Stewart B, Cano MV. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015. Vaccine 2018;36:559-64. [PMID: 29241647 DOI: 10.1016/j.vaccine.2017.11.079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
38 Yong B, Shen J, Liu X, Li F, Chen H, Zhou Q. An intelligent blockchain-based system for safe vaccine supply and supervision. International Journal of Information Management 2020;52:102024. [DOI: 10.1016/j.ijinfomgt.2019.10.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 1] [Article Influence: 11.5] [Reference Citation Analysis]
39 Daley MF, Glanz JM, Newcomer SR, Jackson ML, Groom HC, Lugg MM, McLean HQ, Klein NP, Weintraub ES, McNeil MM. Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule. Vaccine 2017;35:1873-8. [PMID: 28285983 DOI: 10.1016/j.vaccine.2017.02.058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
40 Xu S, Newcomer SR, Kulldorff M, Daley MF, Fireman B, Glanz JM. Use of three summary measures of pediatric vaccination for studying the safety of the childhood immunization schedule. Vaccine 2019;37:1325-31. [PMID: 30709727 DOI: 10.1016/j.vaccine.2019.01.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
41 Petousis-Harris H, Dodd CN. Progress Toward a Global Vaccine Data Network. Pediatr Infect Dis J 2020;39:1023-5. [PMID: 32502124 DOI: 10.1097/INF.0000000000002785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 McNeil MM, Duderstadt SK, Sabatier JF, Ma GG, Duffy J. Vaccination and risk of lone atrial fibrillation in the active component United States military. Hum Vaccin Immunother 2019;15:669-76. [PMID: 30444675 DOI: 10.1080/21645515.2018.1549453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
43 McNeil MM. Vaccine-Associated Anaphylaxis. Curr Treat Options Allergy 2019;6:297-308. [PMID: 31815089 DOI: 10.1007/s40521-019-00215-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
44 Her QL, Malenfant JM, Malek S, Vilk Y, Young J, Li L, Brown J, Toh S. A Query Workflow Design to Perform Automatable Distributed Regression Analysis in Large Distributed Data Networks. EGEMS (Wash DC) 2018;6:11. [PMID: 30094283 DOI: 10.5334/egems.209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
45 Irving SA, Groom HC, Dandamudi P, Daley MF, Donahue JG, Gee J, Hechter R, Jackson LA, Klein NP, Liles E, Myers TR, Stokley S. A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.01.051] [Reference Citation Analysis]
46 Piñeiro Pérez R, Hernández Martín D, Carro Rodríguez MÁ, de la Parte Cancho M, Casado Verrier E, Galán Arévalo S, Carabaño Aguado I. [Vaccination counselling: The meeting point is possible]. An Pediatr (Barc) 2017;86:314-20. [PMID: 27436570 DOI: 10.1016/j.anpedi.2016.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 DeSilva MB, Haapala J, Vazquez-Benitez G, Daley MF, Nordin JD, Klein NP, Henninger ML, Williams JTB, Hambidge SJ, Jackson ML, Donahue JG, Qian L, Lindley MC, Gee J, Weintraub ES, Kharbanda EO. Association of the COVID-19 Pandemic With Routine Childhood Vaccination Rates and Proportion Up to Date With Vaccinations Across 8 US Health Systems in the Vaccine Safety Datalink. JAMA Pediatr 2021. [PMID: 34617975 DOI: 10.1001/jamapediatrics.2021.4251] [Reference Citation Analysis]
48 Wong J, Prieto-Alhambra D, Rijnbeek PR, Desai RJ, Reps JM, Toh S. Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations. Drug Saf 2022;45:493-510. [PMID: 35579813 DOI: 10.1007/s40264-022-01158-3] [Reference Citation Analysis]
49 McCarthy NL, Sukumaran L, Newcomer S, Glanz J, Daley MF, McClure D, Klein NP, Irving S, Jackson ML, Lewin B, Weintraub E. Patterns of childhood immunization and all-cause mortality. Vaccine 2017;35:6643-8. [PMID: 29061349 DOI: 10.1016/j.vaccine.2017.10.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
50 Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31. [PMID: 29939980 DOI: 10.15585/mmwr.rr6701a1] [Cited by in Crossref: 216] [Cited by in F6Publishing: 201] [Article Influence: 54.0] [Reference Citation Analysis]
51 Bardenheier BH, Gravenstein S, Blackman C, Gutman R, Sarkar IN, Feifer RA, White EM, McConeghy K, Nanda A, Mor V. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine 2021;39:3844-51. [PMID: 34092431 DOI: 10.1016/j.vaccine.2021.05.088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Wu D. Correlation of viral load of Hepatitis B with the gestation period and the development of diabetes mellitus. Saudi J Biol Sci. 2019;26:2022-2025. [PMID: 31889788 DOI: 10.1016/j.sjbs.2019.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
53 Plotkin SA, Offit PA, DeStefano F, Larson HJ, Arora NK, Zuber PLF, Fombonne E, Sejvar J, Lambert PH, Hviid A, Halsey N, Garçon N, Peden K, Pollard AJ, Markowitz LE, Glanz J. The science of vaccine safety: Summary of meeting at Wellcome Trust. Vaccine 2020;38:1869-80. [PMID: 31987690 DOI: 10.1016/j.vaccine.2020.01.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
54 Fiks AG, Nekrasova E, Hambidge SJ. Health Systems as a Catalyst for Immunization Delivery. Acad Pediatr 2021;21:S40-7. [PMID: 33958091 DOI: 10.1016/j.acap.2021.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Morris L, Swofford S. Vaccine Safety. Prim Care 2020;47:431-41. [PMID: 32718441 DOI: 10.1016/j.pop.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Moro PL, Li R, Haber P, Weintraub E, Cano M. Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention. Expert Opin Drug Saf 2016;15:1175-83. [PMID: 27268157 DOI: 10.1080/14740338.2016.1194823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
57 Lewandowska A, Lewandowski T, Rudzki G, Rudzki S, Laskowska B. Opinions and Knowledge of Parents Regarding Preventive Vaccinations of Children and Causes of Reluctance toward Preventive Vaccinations. Int J Environ Res Public Health 2020;17:E3694. [PMID: 32456267 DOI: 10.3390/ijerph17103694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Tafreshi SH. Efficacy, safety, and formulation issues of the combined vaccines. Expert Rev Vaccines 2020;19:949-58. [PMID: 33118470 DOI: 10.1080/14760584.2020.1843434] [Reference Citation Analysis]
59 DeStefano F, Shimabukuro TT. The MMR Vaccine and Autism. Annu Rev Virol 2019;6:585-600. [PMID: 30986133 DOI: 10.1146/annurev-virology-092818-015515] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
60 Myers TR, McCarthy NL, Panagiotakopoulos L, Omer SB. Estimation of the Incidence of Guillain-Barré Syndrome During Pregnancy in the United States. Open Forum Infect Dis 2019;6:ofz071. [PMID: 31312665 DOI: 10.1093/ofid/ofz071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
61 Panagiotakopoulos L, McCarthy NL, Tepper NK, Kharbanda EO, Lipkind HS, Vazquez-Benitez G, McClure DL, Greenberg V, Getahun D, Glanz JM, Naleway AL, Klein NP, Nelson JC, Weintraub ES. Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol 2020;136:1086-94. [PMID: 33156197 DOI: 10.1097/AOG.0000000000004166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
62 Guo F, Yang X. A Comprehensive Review of the Management of Pregnant Women with COVID-19: Useful Information for Obstetricians. Infect Drug Resist 2021;14:3363-78. [PMID: 34466003 DOI: 10.2147/IDR.S325496] [Reference Citation Analysis]
63 Haber P, Parashar UD, Haber M, DeStefano F. Intussusception after monovalent rotavirus vaccine-United States, Vaccine Adverse Event Reporting System (VAERS), 2008-2014. Vaccine 2015;33:4873-7. [PMID: 26276687 DOI: 10.1016/j.vaccine.2015.07.054] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
64 Lo Re V 3rd, Klungel OH, Chan KA, Panozzo CA, Zhou W, Winterstein AG. Global covid-19 vaccine rollout and safety surveillance-how to keep pace. BMJ 2021;373:n1416. [PMID: 34144957 DOI: 10.1136/bmj.n1416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
65 Hemkens LG, Goodman SN. Randomized COVID-19 vaccination rollout can offer direct real-world evidence. J Clin Epidemiol 2021:S0895-4356(21)00160-8. [PMID: 34048910 DOI: 10.1016/j.jclinepi.2021.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Naleway AL, Crane B, Irving SA, Bachman D, Vesco KK, Daley MF, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Klein NP, McCarthy NL, McClure DL, Panagiotakopoulos L, Panozzo CA, Vazquez-Benitez G, Weintraub ES, Zerbo O, Kharbanda EO. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf 2021;12:20420986211021233. [PMID: 34178302 DOI: 10.1177/20420986211021233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Daley MF, Clarke CL, Glanz JM, Xu S, Hambidge SJ, Donahue JG, Nordin JD, Klein NP, Jacobsen SJ, Naleway AL, Jackson ML, Lee G, Duffy J, Weintraub E. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. Pharmacoepidemiol Drug Saf 2018;27:59-68. [PMID: 29148124 DOI: 10.1002/pds.4349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol 2018;141:463-72. [PMID: 29413255 DOI: 10.1016/j.jaci.2017.12.971] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 25.7] [Reference Citation Analysis]
69 Zheng C, Yu W, Xie F, Chen W, Mercado C, Sy LS, Qian L, Glenn S, Lee G, Tseng HF, Duffy J, Jackson LA, Daley MF, Crane B, McLean HQ, Jacobsen SJ. The use of natural language processing to identify Tdap-related local reactions at five health care systems in the Vaccine Safety Datalink. Int J Med Inform 2019;127:27-34. [PMID: 31128829 DOI: 10.1016/j.ijmedinf.2019.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
70 Haber P, Tate J, Marquez PL, Moro PL, Parashar U. Safety profile of rotavirus vaccines among individuals aged ≥8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019. Vaccine 2021;39:746-50. [PMID: 33267969 DOI: 10.1016/j.vaccine.2020.11.026] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Mesfin YM, Cheng AC, Enticott J, Lawrie J, Buttery J. Post-vaccination healthcare attendance rate as a proxy measure for syndromic surveillance of adverse events following immunisation. Aust N Z J Public Health 2021;45:101-7. [PMID: 33617131 DOI: 10.1111/1753-6405.13052] [Reference Citation Analysis]
72 Bollaerts K, de Smedt T, Mcgee C, Emborg H, Villa M, Alexandridou M, Duarte-salles T, Gini R, Bartolini C, de Lusignan S, Tin Tin Htar M, Titievsky L, Sturkenboom M, Bauchau V. ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases. Vaccine 2020;38:B76-83. [DOI: 10.1016/j.vaccine.2019.08.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
73 Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, Koneru A, Haber P, Hagan L, Romero JR, Schillie S, Harris AM. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69:1-38. [PMID: 32614811 DOI: 10.15585/mmwr.rr6905a1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
74 Drees M, Gerber JS, Morgan DJ, Lee GM. Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship: Use of Administrative and Surveillance Databases. Infect Control Hosp Epidemiol 2016;37:1278-87. [DOI: 10.1017/ice.2016.189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
75 Carter-Pokras O, Hutchins S, Gaudino JA, Veeranki SP, Lurie P, Weiser T, DeMarco M, Khan NF, Cordero JF. The role of epidemiology in informing United States childhood immunization policy and practice. Ann Epidemiol 2020;62:100-14. [PMID: 33065268 DOI: 10.1016/j.annepidem.2020.09.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Duffy J, Weintraub E, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, Lee GM, Marcy SM, Nakasato CC, Naleway A, Omer SB, Vellozzi C, DeStefano F; Vaccine Safety Datalink. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics 2016;138:e20160320. [PMID: 27273711 DOI: 10.1542/peds.2016-0320] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
77 McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, Hambidge SJ, Lee GM, Jackson LA, Irving SA, King JP, Kharbanda EO, Bednarczyk RA, DeStefano F. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016;137:868-78. [PMID: 26452420 DOI: 10.1016/j.jaci.2015.07.048] [Cited by in Crossref: 141] [Cited by in F6Publishing: 116] [Article Influence: 20.1] [Reference Citation Analysis]
78 Phillips A, Carlson S, Danchin M, Beard F, Macartney K. From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years. Vaccine 2021:S0264-410X(21)00950-6. [PMID: 34376308 DOI: 10.1016/j.vaccine.2021.07.059] [Reference Citation Analysis]
79 Kenigsberg TA, Hause AM, Mcneil MM, Nelson JC, Ann Shoup J, Goddard K, Lou Y, Hanson KE, Glenn SC, Weintraub E. Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the Vaccine Safety Datalink. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.04.010] [Reference Citation Analysis]
80 Moro PL, Panagiotakopoulos L, Oduyebo T, Olson CK, Myers T. Monitoring the safety of COVID-19 vaccines in pregnancy in the US. Hum Vaccin Immunother 2021;:1-9. [PMID: 34756131 DOI: 10.1080/21645515.2021.1984132] [Reference Citation Analysis]
81 Glanz JM, Newcomer SR, Daley MF, Mcclure DL, Baxter RP, Jackson ML, Naleway AL, Lugg MM, Destefano F. Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children. Vaccine 2015;33:6736-44. [DOI: 10.1016/j.vaccine.2015.10.076] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
82 Perez-Vilar S, Hu M, Weintraub E, Arya D, Lufkin B, Myers T, Woo EJ, Lo AC, Chu S, Swarr M, Liao J, Wernecke M, MaCurdy T, Kelman J, Anderson S, Duffy J, Forshee RA. Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season. J Infect Dis 2021;223:416-25. [PMID: 33137184 DOI: 10.1093/infdis/jiaa543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
83 Glanz JM, Clarke CL, Xu S, Daley MF, Shoup JA, Schroeder EB, Lewin BJ, McClure DL, Kharbanda E, Klein NP, DeStefano F. Association Between Rotavirus Vaccination and Type 1 Diabetes in Children. JAMA Pediatr 2020;174:455-62. [PMID: 32150236 DOI: 10.1001/jamapediatrics.2019.6324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
84 DeStefano F, Chen RT, Izurieta HS, Raine JM. ADVANCE: The promises, pitfalls, and future prospects of a European distributed data network for immunization surveillance and research. Vaccine 2020;38 Suppl 2:v-vi. [PMID: 33342487 DOI: 10.1016/j.vaccine.2020.12.029] [Reference Citation Analysis]
85 Regan AK. The safety of maternal immunization. Hum Vaccin Immunother 2016;12:3132-6. [PMID: 27541370 DOI: 10.1080/21645515.2016.1222341] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
86 McClure DL, Jacobsen SJ, Klein NP, Naleway AL, Kharbanda EO, Glanz JM, Jackson LA, Weintraub ES, McLean HQ. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine 2019;37:76-9. [PMID: 30478005 DOI: 10.1016/j.vaccine.2018.11.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
87 Sukumaran L, McCarthy NL, Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Jackson L, Klein NP, Naleway AL, McClure DL, Hechter RC, Kawai AT, Glanz JM, Weintraub ES. Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics 2018;141:e20173310. [PMID: 29463582 DOI: 10.1542/peds.2017-3310] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
88 Moro PL, Haber P, McNeil MM. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention. Expert Rev Vaccines 2019;18:1091-101. [PMID: 31580725 DOI: 10.1080/14760584.2019.1676154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
89 Garg I, Shekhar R, Sheikh AB, Pal S. COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines. Infect Dis Rep 2021;13:685-99. [PMID: 34449637 DOI: 10.3390/idr13030064] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
90 Hambidge SJ, Ross C, Shoup JA, Wain K, Narwaney K, Breslin K, Weintraub ES, McNeil MM. Integration of data from a safety net health care system into the Vaccine Safety Datalink. Vaccine 2017;35:1329-34. [PMID: 28161424 DOI: 10.1016/j.vaccine.2017.01.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
91 Duffy J, Lewis M, Harrington T, Baxter R, Belongia EA, Jackson LA, Jacobsen SJ, Lee GM, Naleway AL, Nordin J, Daley MF; Vaccine Safety Datalink. Live attenuated influenza vaccine use and safety in children and adults with asthma. Ann Allergy Asthma Immunol 2017;118:439-44. [PMID: 28390584 DOI: 10.1016/j.anai.2017.01.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
92 Kang G, Tang F, Wang Z, Hu R, Yu J, Gao J. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China. Hum Vaccin Immunother 2021;17:2568-74. [PMID: 33780310 DOI: 10.1080/21645515.2021.1898306] [Reference Citation Analysis]
93 Liu Z, Zhang L, Yang Y, Meng R, Fang T, Dong Y, Li N, Xu G, Zhan S. Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China. J Med Internet Res 2020;22:e17446. [PMID: 32234696 DOI: 10.2196/17446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
94 Vickers ER, McClure DL, Naleway AL, Jacobsen SJ, Klein NP, Glanz JM, Weintraub ES, Belongia EA. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. Vaccine 2017;35:5872-7. [PMID: 28888342 DOI: 10.1016/j.vaccine.2017.08.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
95 Newcomer SR, Kulldorff M, Xu S, Daley MF, Fireman B, Lewis E, Glanz JM. Bias from outcome misclassification in immunization schedule safety research. Pharmacoepidemiol Drug Saf 2018;27:221-8. [PMID: 29292551 DOI: 10.1002/pds.4374] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
96 Shay DK, Shimabukuro TT, DeStefano F. Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines. JAMA Cardiol 2021. [PMID: 34185047 DOI: 10.1001/jamacardio.2021.2821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
97 Newcomer SR, Daley MF, Narwaney KJ, Xu S, DeStefano F, Groom HC, Jackson ML, Lewin BJ, McLean HQ, Nordin JD, Zerbo O, Glanz JM. Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age. Pediatr Infect Dis J 2020;39:247-53. [PMID: 32032310 DOI: 10.1097/INF.0000000000002550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Izurieta HS, Moro PL, Chen RT. Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries? Vaccine 2018;36:345-6. [PMID: 29033065 DOI: 10.1016/j.vaccine.2017.10.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Zhou H, Thompson WW, Belongia EA, Fowlkes A, Baxter R, Jacobsen SJ, Jackson ML, Glanz JM, Naleway AL, Ford DC, Weintraub E, Shay DK. Estimated rates of influenza-associated outpatient visits during 2001-2010 in 6 US integrated healthcare delivery organizations. Influenza Other Respir Viruses 2018;12:122-31. [PMID: 28960732 DOI: 10.1111/irv.12495] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
100 Wang SV, Stefanini K, Lewis E, Newcomer SR, Fireman B, Daley MF, Glanz JM, Duffy J, Weintraub E, Kulldorff M. Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event. Drug Saf 2020;43:1057-65. [PMID: 32613596 DOI: 10.1007/s40264-020-00967-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
101 Xu S, Clarke CL, Newcomer SR, Daley MF, Glanz JM. Analyzing self-controlled case series data when case confirmation rates are estimated from an internal validation sample. Biom J 2018;60:748-60. [PMID: 29768667 DOI: 10.1002/bimj.201700088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Pillsbury AJ, Glover C, Jacoby P, Quinn HE, Fathima P, Cashman P, Leeb A, Blyth CC, Gold MS, Snelling T, Macartney KK. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open 2018;8:e023263. [PMID: 30341132 DOI: 10.1136/bmjopen-2018-023263] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
103 Yih WK, Kulldorff M, Sandhu SK, Zichittella L, Maro JC, Cole DV, Jin R, Kawai AT, Baker MA, Liu C, McMahill-Walraven CN, Selvan MS, Platt R, Nguyen MD, Lee GM. Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System. Pharmacoepidemiol Drug Saf 2016;25:481-92. [PMID: 26572776 DOI: 10.1002/pds.3908] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
104 Narwaney KJ, Breslin K, Ross CA, Shoup JA, Wain KF, Weintraub ES, McNeil MM, Hambidge SJ. Vaccine adverse events in a safety net healthcare system and a managed care organization. Vaccine 2017;35:1335-40. [PMID: 28185740 DOI: 10.1016/j.vaccine.2017.01.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
105 Sturkenboom M. Advancing collaborative vaccine benefits and safety research in Europe via the ADVANCE code of conduct. Vaccine 2018;36:194-5. [DOI: 10.1016/j.vaccine.2017.08.043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
106 Sukumaran L, McCarthy NL, Kharbanda EO, McNeil MM, Naleway AL, Klein NP, Jackson ML, Hambidge SJ, Lugg MM, Li R, Weintraub ES, Bednarczyk RA, King JP, DeStefano F, Orenstein WA, Omer SB. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA 2015;314:1581-7. [PMID: 26501534 DOI: 10.1001/jama.2015.12790] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
107 Groom HC, Smith N, Irving SA, Koppolu P, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Klein NP, McCarthy NL, Nordin JD, Panagiotakopoulos L, Naleway AL. Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine 2019;37:6648-55. [PMID: 31548013 DOI: 10.1016/j.vaccine.2019.09.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
108 Duffy J, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, Naleway A, Omer SB, Weintraub E; Vaccine Safety Datalink. Febrile Seizure Risk after Vaccination in Children One to Five Months of Age. Pediatr Neurol 2017;76:72-8. [PMID: 28958404 DOI: 10.1016/j.pediatrneurol.2017.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
109 . Overcoming Barriers and Identifying Opportunities for Developing Maternal Immunizations: Recommendations From the National Vaccine Advisory Committee. Public Health Rep 2017;132:271-84. [PMID: 28379782 DOI: 10.1177/0033354917698118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
110 Bollaerts K, Ledent E, de Smedt T, Weibel D, Emborg HD, Danieli G, Duarte-Salles T, Huerta-Alvarez C, Martín-Merino E, Picelli G, Tramontan L, Sturkenboom M, Bauchau V. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling. Vaccine 2020;38 Suppl 2:B65-75. [PMID: 31677947 DOI: 10.1016/j.vaccine.2019.09.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
111 Daley MF, Reifler LM, Shoup JA, Narwaney KJ, Kharbanda EO, Groom HC, Jackson ML, Jacobsen SJ, McLean HQ, Klein NP, Williams JTB, Weintraub ES, McNeil MM, Glanz JM. Temporal Trends in Undervaccination: A Population-Based Cohort Study. Am J Prev Med 2021;61:64-72. [PMID: 34148627 DOI: 10.1016/j.amepre.2021.01.037] [Reference Citation Analysis]
112 Moro PL, McNeil MM, Sukumaran L, Broder KR. The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States. Hum Vaccin Immunother 2015;11:2872-9. [PMID: 26378718 DOI: 10.1080/21645515.2015.1072664] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
113 Connolly JG, Wang SV, Fuller CC, Toh S, Panozzo CA, Cocoros N, Zhou M, Gagne JJ, Maro JC. Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network. Curr Epidemiol Rep 2017;4:298-306. [PMID: 29204333 DOI: 10.1007/s40471-017-0121-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]